Design of the PF-ILD trial: A double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

BMJ Open Respiratory Research

Volumn 4, Issue 1, 2017, Pages

  Flaherty, Kevin R ^a   Brown, Kevin K ^b   Wells, Athol U ^c   Clerisme Beaty, Emmanuelle ^d   Collard, Harold R ^e   Cottin, Vincent ^f   Devaraj, Anand ^c   Inoue, Yoshikazu ^g   Le Maulf, Florence ^h   Richeldi, Luca ⁱ   Schmidt, Hendrik ^j   Walsh, Simon ^k   Mezzanotte, William ^d   Schlenker Herceg, Rozsa ^j  

^a UNIVERSITY OF MICHIGAN   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITÉ LYON 1   (France)

^g NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^h BOEHRINGER INGELHEIM   (France)

ⁱ FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^k KING S COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

interstitial fibrosis; rare lung diseases

Indexed keywords

NINTEDANIB; PLACEBO;

ADULT; ALL CAUSE MORTALITY; ALLERGIC PNEUMONITIS; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DEATH; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL LUNG DISEASE; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SARCOIDOSIS; SCREENING;

EID: 85034622494     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2017-000212     Document Type: Article

References (38)

1. Valeyre D, Duchemann B, Nunes H, et al; Interstitial lung diseases. In: Annesi-Maesano I, Lundbäck B, Viegi G, eds. Respiratory epidemiology, 2014:79-87.
2. Walsh SL, Sverzellati N, Devaraj A, et al. Connective tissue disease related fbrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014;69:216-22.
3. Travis WD, Costabel U, Hansell DM, et al. An offcial American Thoracic Society/European respiratory society statement: Update of the international multidisciplinary classifcation of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
4. Akira M, Inoue Y, Arai T, et al. Long-term follow-up high-resolution CT fndings in non-specifc interstitial pneumonia. Thorax 2011;66:61-5.
5. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010;35:1322-8.
6. White ES, Borok Z, Brown KK, et al. An American Thoracic society offcial research statement: future directions in lung fbrosis research. Am J Respir Crit Care Med 2016;193:792-800.
7. Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fbrotic effects of nintedanib in lung fbroblasts derived from patients with idiopathic pulmonary fbrosis. Respir Res 2014;15:157.
8. Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fbroblast activation and ameliorates fbrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 2016;75:883-90.
9. Wollin L, Maillet I, Quesniaux V, et al. Antifbrotic and anti-infammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fbrosis. J Pharmacol Exp Ther 2014;349:209-20.
10. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fbrosis. Eur Respir J 2015;45:1434-45.
11. Richeldi L, Cottin V, Flaherty KR, et al. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fbrosis. Respir Med 2014;108:1023-30.
12. Richeldi L, du Bois RM, Raghu G, et al. Effcacy and safety of nintedanib in idiopathic pulmonary fbrosis. N Engl J Med 2014;370:2071-82.
13. Raghu G, Collard HR, Egan JJ, et al. An offcial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fbrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
14. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
15. Hochberg Y. A sharper Bonferroni procedure for multiple tests of signifcance. Biometrika 1988;75:800-2.
16. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007;6:227-44.
17. Ahmad K, Barba T, Gamondes D, et al. Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med 2017;123:56-62.
18. Agostini C, Albera C, Bariff F, et al. First report of the Italian register for diffuse infltrative lung disorders (RIPID). Monaldi Arch Chest Dis 2001;56:364-8.
19. Collard HR, King TE, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fbrosis. Am J Respir Crit Care Med 2003;168:538-42.
20. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fbrosis. Am J Respir Crit Care Med 2011;184:459-66.
21. du Bois RM, Nathan SD, Richeldi L, et al. Idiopathic pulmonary fbrosis: Lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012;186:712-5.
22. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-7.
23. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fbrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-9.
24. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8.
25. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fbrosis. Thorax 2012;67:407-11.
26. Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fbrosis and emphysema. Eur Respir J 2011;38:176-83.
27. Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fbrosis disease course from past trends in pulmonary function. Chest 2014;145:579-85.
28. Solomon JJ, Chung JH, Cosgrove G P, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016;47:588-96.
29. Strand MJ, Sprunger D, Cosgrove G P, et al. Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest 2014;146:775-85.
30. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fbrosis. Eur Respir J 2010;35:830-6.
31. The U.S.Food and Drug Administration's (FDA's) patient-focused drug development initiative. The voice of the patient. 2015 http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugU serFee/UCM440829.pdf (accessed 22 Nov 2016).
32. Saketkoo LA, Mittoo S, Frankel S, et al. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J Rheumatol 2014;41:792-8.
33. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012;67:804-10.
34. Sharp C, Baggott C, Lamb H, et al. The association between functional and HRQOL (K-BILD) outcome measures in IPF and other fbrotic ILDs. Eur Respir J 2016;40(Suppl 60().
35. Sinha A, Patel AS, Siegert R, et al. The King's brief interstitial lung disease (K-BILD) questionnaire; an updated minimal important difference. Eur Respir J 2016;48(Suppl 60().
36. Patel AS, Siegert RJ, Keir GJ, et al. The minimal important difference of the King's brief interstitial Lung disease questionnaire (K-BILD) and forced vital capacity in interstitial Lung disease. Respir Med 2013;107:1438-43.
37. King TE, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fbrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014;189:825-31.
38. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for industry. Enrichment strategies for clinical trials to support approval of human drugs and biological products. Draft guidance, 2012. http://w ww.f da.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf. (accessed 27 Oct 2016).